AC Immune SA expected to post a loss of 14 rappen a share - Earnings Preview

AC Immune SA

24/04/2024 14:15

* AC Immune SA  ACIU.OQ   ACIU.O  is expected to show a rise
in
quarterly revenue when it reports  results on April 26
(estimated) for the period ending March 31 2024
    * The Lausanne Vaud-based  company is expected to report
revenue
of CHF5.327 million, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for AC Immune SA is for a
loss
of 14 rappen per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 2,098.8% in the last three months. ​
    * Wall Street's median 12-month price target for AC Immune
SA is
$9.00​, above​ its last closing price of $2.38. ​​​

Previous quarterly performance (using preferred earnings measure
in Swiss francs). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.06       -0.11      -0.05     Beat    55.9
 Sep. 30 2023  -0.07       0.03       -0.18     Missed  -801.2
 Jun. 30 2023  -0.19       -0.20      -0.20     Met     -1.4​
 Mar. 31 2023  -0.23       -0.23      -0.21     Beat    8.5
 ​​Dec.                    -0.25      -0.23     Beat    8.7
 31 2022                                                
 Sep. 30 2022  -0.27       -0.24      -0.16     Beat    33.8​
 Jun. 30 2022  -0.25       -0.23      -0.23     Met     1
 Mar. 31 2022  -0.22       -0.22      -0.23     Missed  -3.8
 This summary was machine generated April 24 at 13:15 GMT.  All
figures in Swiss francs unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)